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Abstract
Background: Oxaliplatin is a platinum-based chemotherapeutic drug. Neurotoxicity is the dose-
limiting side effect. Previous investigations have reported that acute neurotoxicity could be
mediated via voltage-gated ion channels. A possible mechanism for some of the effects is a
modification of surface charges around the ion channel, either because of chelation of extracellular
Ca2+, or because of binding of a charged biotransformation product of oxaliplatin to the channel.
To elucidate the molecular mechanism, we investigated the effects of oxaliplatin and its chloride
complex [Pt(dach)oxCl]- on the voltage-gated Shaker K channel expressed in Xenopus oocytes. The
recordings were made with the two-electrode and the cut-open oocyte voltage clamp techniques.
Conclusion: To our surprise, we did not see any effects on the current amplitudes, on the current
time courses, or on the voltage dependence of the Shaker wild-type channel. Oxaliplatin is
expected to bind to cysteines. Therefore, we explored if there could be a specific effect on single
(E418C) and double-cysteine (R362C/F416C) mutated Shaker channels previously shown to be
sensitive to cysteine-specific reagents. Neither of these channels were affected by oxaliplatin. The
clear lack of effect on the Shaker K channel suggests that oxaliplatin or its monochloro complex
has no general surface-charge effect on the channels, as has been suggested before, but rather a
specific effect to the channels previously shown to be affected.
Background
The platinum-based chemotherapeutic drug oxaliplatin
has been used in the clinic for about ten years. The thera-
peutic indication is metastatic colorectal cancer. The
mechanism of action is not fully understood, but it is
assumed that DNA-adduct formation is one route to cell
destruction [1]. The dose-limiting side effect of oxaliplatin
treatment is neurotoxicity. A unique and unpleasant acute
neurosensory toxicity with paresthesias and dysesthesias
of the distal extremities and perioral region occurs shortly
after infusion in as much as 90% of the patients. These
symptoms can be worsened or triggered by cold, but are
reversed within hours or days after treatment. After cumu-
lative doses of about 800 mg/m2 another form of neuro-
toxicity, with paresthesias and dysesthesias persisting
between cycles and problems with sensorimotor coordi-
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nation is seen in about 10–15% of the patients. Most of
the patients recover a few months after treatment discon-
tinuation [2,3]. Many patients who receive a clinical ben-
efit from oxaliplatin cannot continue treatment because
of worsening neurotoxicity. Our understanding of the
mechanism underlying this is limited and research in this
area could lead to prolonged treatment with this useful
drug.
Oxaliplatin has a half-life of about 14 minutes in vivo and
the maximal blood concentration after a 2-hour infusion
of 85 mg/m2 is 3.6 μM [4]. The short half-life is explained,
at least in part, by the reaction of oxaliplatin with chlo-
ride, glutathione, methionine, and cysteine at physiologi-
cal concentrations [5]. It has been suggested that
biotransformation products of oxaliplatin may be respon-
sible for the neurotoxic side effects [6].
Because the symptoms of acute neurotoxicity may be
related to hyperexcitability of sensory neurons, the effects
of oxaliplatin on voltage-gated Na and K channels,
responsible for the shape of the neuronal action potential,
have been examined. Oxaliplatin, in the concentration
range from 1 to 500 μM, has been shown to affect both Na
and K channels [7-11]. Even though these studies on dif-
ferent preparations report on slightly different effects,
there seems to be a general theme: The voltage depend-
ence for the Na and K channels is changed (less positive
voltages are needed to open the channels), and the Na
current inactivation becomes slower and less complete.
Because the voltage dependences of both Na and K chan-
nels have been reported to be shifted in negative direction
along the voltage axis it is tempting to speculate about a
common underlying mechanism. One such possible
mechanism is a change of the transmembrane electrical
field sensed by the voltage sensor of the ion channels. The
voltage sensor is a positively charged α-helix responding
to changes in the membrane electric field to open the gate
of the ion channel [12]. Metal ions are well known shifters
of the channels' voltage dependence along the voltage
axis; an increase in the concentration of positive metal
ions makes it harder for the positively charged voltage
sensor to open the channel and a decrease in the concen-
tration has the opposite effect [13]. Other molecules with
shift capacity are polyunsaturated free fatty acids; the neg-
atively charged free fatty acids bind close to the voltage
sensor and thereby electrostatically activate the channel
by shifting the channels voltage dependence along the
voltage axis [14]. Thus, the oxaliplatin effect can be caused
either (1) indirectly by chelating extracellular calcium
ions by oxalate derived from oxaliplatin, or (2) directly by
binding the negatively charged chloride complex of oxali-
platin to the channel. In both cases the positively charged
voltage sensor will be electrostatically attracted to the
extracellular side, thereby activating the channel. To inves-
tigate these hypotheses, we explored the effects of oxalipl-
atin and its chloride complex on the well-characterized
voltage-gated Shaker K channel expressed in Xenopus
oocytes.
Results
Previous investigations have reported effects of oxalipla-
tin on voltage-gated ion channels. Here, we explored the
effect of extracellularly applied oxaliplatin and its mono-
chloro complex ([Pt(dach)oxCl]-, Fig. 1) on a well studied
voltage-gated K channel, the Shaker K channel expressed
in Xenopus oocytes.
Chemical structures Figure 1
Chemical structures. Chemical structures of oxaliplatin, the monochloro monooxalato oxaliplatin complex ([Pt(dach)oxCl]-
), and the dichloro oxaliplatin complex (Pt(dach)Cl2).Journal of Negative Results in BioMedicine 2009, 8:2 http://www.jnrbm.com/content/8/1/2
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Oxaliplatin or [Pt(dach)oxCl]- does not affect the voltage 
dependence of the wild-type Shaker K channel
We first tested 60 μM oxaliplatin in a Cl--free extracellular
solution with the high-resolution cut-open oocyte tech-
nique where the oocyte is sandwiched between two holes
of two Perspex chambers. The cut-open oocyte technique
reduces the capacitive current and thereby allows analysis
of the activation time course in detail [15]. The reason for
using the Cl- -free solution was to avoid any endogenous
Cl- current which could be provoked by the cut-open
oocyte technique. No visible effects were seen, neither on
the time course, the amplitude, nor on the channel's volt-
age dependence (n = 5; data not shown). One possible
explanation for the lack of effect is that it is only
[Pt(dach)oxCl]- that exerts effect. Therefore similar exper-
iments with the two-electrode voltage clamp technique
were carried out with oxaliplatin added to a Cl- -contain-
ing (0.1 M) extracellular solution. Fig. 2A and 2B show a
control voltage-clamp family, and a voltage-clamp family
with 240 μM oxaliplatin added to the extracellular solu-
tion. Fig. 2C shows the corresponding conductance versus
voltage, GK(V), curves calculated as described in Methods.
Since most experiments were carried out immediately
after the addition of oxaliplatin, a mixture prepared as
described in Methods was added to the extracellular fluid
to be certain that the oocytes would be exposed to
[Pt(dach)oxCl]-. Again, the K channels remained unaf-
fected by this treatment. Totally 31 oocytes expressing
Shaker wild-type channel Figure 2
Shaker wild-type channel. Oxaliplatin does not affect the Shaker wild-type channel. A) Current family in control solution. 
Voltage steps between -80 mV and 0 mV in steps of 10 mV. Holding voltage = -80 mV. Time between each step is 2 s. Record-
ings done by the two-electrode voltage clamp technique. B) Current family with 240 μM oxaliplatin added to the extracellular 
solution. C) Conductance versus voltage curve for the data from A and B.Journal of Negative Results in BioMedicine 2009, 8:2 http://www.jnrbm.com/content/8/1/2
Page 4 of 8
(page number not for citation purposes)
wild-type channels were investigated with concentrations
of oxaliplatin in the range from 60 to 1000 μM. No shift
of the GK(V) curve was seen.
For Na channels, it has been reported that the fast inacti-
vation is slowed down considerably [7,8]. To see if this is
also applicable to K channels we investigated the effect of
oxaliplatin on a fast inactivating K channel (Shaker B). No
effect on the inactivation was seen when 60 μM oxalipla-
tin was added to the extracellular solution (n = 2; data not
shown).
Oxaliplatin or [Pt(dach)oxCl]- does not affect a cysteine-
mutated Shaker K channel
Oxaliplatin is expected to bind to cysteines [5]. Therefore,
another explanation for the lack of effects of oxaliplatin is
that a critically exposed cysteine residue is lacking in the
wild-type channel. To explore this we used the 418C
mutation which has a very critical cysteine residue
exposed to the extracellular solution. In a previous study
we showed that modification of this residue had a large
effect on the gating [16]. Fig. 3A shows a voltage-clamp
family of 418C currents and Fig. 3B shows that the current
Cysteine-enriched Shaker channel Figure 3
Cysteine-enriched Shaker channel. Oxaliplatin does not affect a cysteine-enriched Shaker (E418C) channel. A) Current 
family in control solution. Voltage steps between -40 and +60 mV in steps of 20 mV. Holding voltage = -80 mV. Time between 
each step is 2 min to allow complete recovery after inactivation [16]. Two-electrode voltage clamp in A and B. B) Current fam-
ily after complete modification of the positively charged MTSET. This shows that 418C is very sensitive to modification. C) 
Another control recording similar to that in A. Cut-open oocyte voltage clamp in C and D. D) Addition of 60 μM oxaliplatin 
does not affect the currents.Journal of Negative Results in BioMedicine 2009, 8:2 http://www.jnrbm.com/content/8/1/2
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is almost completely abolished after modification with
the cysteine-specific reagent MTSET. Wild-type Shaker K
channels are not affected by MTSET (data not shown).
Again, addition of oxaliplatin failed to affect the currents
(Fig. 3C and 3D), suggesting that no binding to or modi-
fication of 418C occurs (n = 8).
Oxaliplatin or [Pt(dach)oxCl]- does not affect a double 
cysteine-mutated Shaker K channel
Some substances, like Cd2+, have a much larger effect on
two neighbouring cysteines than on a single cysteine [17].
In this case Cd2+ makes a metal ion bridge between the
two residues. We investigated if a double cysteine muta-
tion (362C/416C), with the cysteines close enough to
each other to cause a disulfide bond [18], could coordi-
nate with a platinum complex. Once again, we could not
detect any such effects (Fig. 4) (n = 5).
Discussion
In the present investigation we showed that oxaliplatin
and its chloride complex [Pt(dach)oxCl]- did not have any
effects on the Shaker K channel, neither on wild-type
(both inactivating and non-inactivating) nor on cysteine-
mutated channels (418C, 362C/416C). This suggests that
Double-cysteine-mutated Shaker channel Figure 4
Double-cysteine-mutated Shaker channel. Oxaliplatin does not affect a double-cysteine-mutated Shaker (R362C/F416C) 
channel. A) Current family in control solution. Voltage steps between -80 and +30 mV in steps of 10 mV. Holding voltage = -80 
mV. Time between each step is 2 s. B) Current family with 240 μM oxaliplatin added to the extracellular solution. C) Conduct-
ance versus voltage curve for the data from A and B. The experiments were carried out in Cl- -containing solutions with the 
two-electrode voltage clamp technique.Journal of Negative Results in BioMedicine 2009, 8:2 http://www.jnrbm.com/content/8/1/2
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the neurotoxic side effects reported for oxaliplatin cannot
be explained with general effects on the channels' voltage
dependences.
Neurotoxicity of oxaliplatin and its degradation products
Oxaliplatin therapy gives rise to two distinct types of neu-
rotoxicity. One appears after relatively high cumulative
doses (10–15% incidence at 800 mg/m2) [2] and this side
effect seems to be comparable to the neurotoxicity seen
after cisplatin and ormaplatin use and has been shown to
affect dorsal root ganglion neurons [6,19-22]. The other
type of neurotoxicity is an acute form that appears during
or within hours or days after administration [3].
The reaction of oxaliplatin with chloride has previously
been unravelled [23]. A ring-opened intermediate, the
monochloro-monooxalato complex (Fig. 1) is rapidly
formed (within 30 minutes) in physiologic in vitro condi-
tions, constituting about 10% of the intact oxaliplatin. We
hypothesized that this reaction product, which is nega-
tively charged, might be responsible for the acute neuro-
toxic side effects of oxaliplatin treatment. As mentioned in
the Introduction, adding positively charged metal ions
shift the channel's voltage dependence in positive direc-
tion along the voltage axis [13], while negatively charged
compounds shift the voltage dependence in negative
direction [14]. Similar electrostatic effects have also been
demonstrated for covalent modification of cysteines with
reagents of different charge [24].
We know that oxaliplatin is highly reactive towards sul-
phur containing compounds [5]. The half-life of oxalipla-
tin in the presence of 2.5 mM cysteine is for example less
than 20 minutes. Some K channel mutations used in the
present investigation have target sulphur-containing
amino acids (cysteine) at the surface. In spite of this, no
measurable effect of oxaliplatin on these ion channel sub-
types was recorded. This surprising lack of effect may sug-
gest that the cysteines on the channels surface does not
react with oxaliplatin, despite high reactivity with other
cysteine-specific reagents [18,24]. This also suggests that it
is unlikely that oxaliplatin-induced side effect is caused by
any covalent modification of channel cysteines.
Comparison with previous electrophysiological studies
Several previous investigations have reported acute effects
on voltage-gated ion channels, and the oxaliplatin-
induced side effects have been suggested to be caused by
effects on these voltage-gated ion channels [7-11]. Four of
these studies report on positive Na channel effects and
two on K channel effects. However, in most of these inves-
tigations, very high concentrations of oxaliplatin were
used. The maximum blood concentration of intact oxali-
platin after a 2-hour infusion of 85 mg/m2 is 3.6 μM [4].
Three of the studies only used high concentrations of 25–
500 μM [7-9], while two of the studies (both of which
reported on K channel effects) used more physiologically
relevant concentrations down to 1 μM [10,11].
General mechanisms have been suggested. 1) Oxalate lib-
erated from oxaliplatin could exert general effects by
chelating Ca2+ and thereby affecting fixed surface charges
[7,10]. The present study does not support such a mecha-
nism, since no effects were seen in the ion channel setting
in spite of different amounts of oxalate released from
oxaliplatin using varying exposure times (5 min-12 h) and
concentrations (60–1000 μM). Furthermore, it is difficult
to understand how the relatively small in vivo concentra-
tions of oxalate could be sufficient to deplete the extracel-
lular calcium pool of about 1 mM. Moreover, since the
intracellular Ca2+ concentration is in the μM range, forma-
tion of calcium oxalate intracellularly, as suggested by
Grolleau et al [7], as a precipitate or an ion pair is highly
unlikely [25]. Intracellular Ca2+ has been reported not to
be affected by extracellular oxaliplatin [9]. 2) Another
possibility is that the negatively charged monochloro-
monooxalato complex (Fig. 1) exerts general effects by
binding directly to ion channels (one of the hypotheses
put forward in the present investigation). Neither this is
supported in the present investigation.
A negative shift in the voltage dependence of Na-channel
activation that could be responsible for the hyperexcita-
bility seen in the acute oxaliplatin side effects was detected
in some investigations [8,10]. A slowing of the Na-chan-
nel inactivation could also promote hyperexcitability. In
some Na channels, such a slowing has been reported
[8,9], while it is lacking in other Na channels [8,10]. All
together, this points to channel-specific effects rather than
general effects.
Conclusion
Oxaliplatin at relatively high concentrations has been
reported to affect the voltage dependence of some ion
channels. Here, we have shown that these reported effects
are not unspecific channel effects and that these effects are
probably not mediated via binding to cysteine amino acid
residues. Instead, we propose that the side effects of oxali-
platin are caused by specific channel effects, most likely a
slowing of inactivation in some Na channels.
Methods
Molecular biology and expression of ion channels
The experiments were performed on the Shaker H4 potas-
sium channel [26], made incapable of fast-inactivation by
the  Δ6–46 deletion [27], and on the fast inactivating
Shaker B channel [28]. For the experiments with cysteine-
mutated Shaker H4 channels we used the mutations
E418C [16] and R362C/F416C [18]. cRNA was tran-
scribed using the T7 mMessage mMachine kit (AmbionJournal of Negative Results in BioMedicine 2009, 8:2 http://www.jnrbm.com/content/8/1/2
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Inc., Austin, TX, USA) and injected in Xenopus laevis
oocytes (20–500 pg/cell) using a Nanoject injector
(Drummond Scientific Co., Broomall, PA, USA). The
oocytes were maintained in a modified Barth's solution
(MBS, in mM: 88 NaCl, 1 KCl, 2.4 NaHCO3, 15 HEPES,
0.33 Ca(NO3)2, 0.41 CaCl2, and 0.82 MgSO4) adjusted to
pH 7.5 by NaOH, and supplemented with penicillin (10
μg/ml), streptomycin (10 μg/ml) and sodium pyruvate
(10  μg/ml). The electrophysiological experiments were
made 3–5 days after injection of mRNA.
Electrophysiology and analysis
Totally, 50 oocytes expressing inactivating, non-inactiva-
tion, or cysteine-mutated Shaker K channels were investi-
gated with different concentrations of the platinum drug.
The currents were measured with the two-electrode volt-
age clamp technique or the cut-open oocyte voltage clamp
technique (CA-1 amplifier, Dagan Corporation, Minneap-
olis, MN, USA) as previously described [15,16,29]. Micro-
electrodes were made from borosilicate glass and filled
with a 3 M KCl solution. The resulting resistance varied
between 0.5 and 2.0 MΩ. For the two-electrode recordings
we used the 1 K solution (in mM: 88 NaCl, 15 HEPES, 1
KCl, 0.8 MgCl2, and 0.4 CaCl2) adjusted to pH 7.4 by
NaOH. For the cut-open oocyte recordings, the solutions
in the (extracellular) top pool and the guard pool were
composed of (in mM): 107 KOH, 107 methanesulfonic
acid, 10 HEPES, and 2 CaCl2. The solution in the (intrac-
ellular) lower pool was (in mM): 110 KOH, 110 meth-
anesulfonic acid, 10 HEPES, and 0.1 EGTA. The
amplifier's capacitance and leak compensation were used,
and the currents were low pass filtered at 5 kHz. All exper-
iments were carried out at room temperature (20–23°C).
To covalently modify a substituted cysteine, the mem-
brane-impermeant thiol reagent MTSET ([2-(trimethyl-
ammonium)ethyl]methanethiosulfonate bromide)
(Toronto Research Chemicals Inc., North York, Ontario,
Canada), was applied continuously in the bath solution
by a gravity-driven perfusion system. The cysteine reagent
was applied to saturation (1 mM for 1 minute) followed
by carefully washing off MTSET.
The steady-state K conductance GK(V) was calculated as
GK(V) = IK(V)/(V - EK), where IK(V) is the steady-state cur-
rent,V is the membrane potential measured in the bulk
solutions, and EK is the equilibrium potential (-80 mV).
To make sure that the platinum-based substances reach
the ion channels and do not get stuck in the vitelline layer
surrounding the Xenopus oocytes, we tested the effects on
oocytes with the vitelline layer mechanically removed. No
difference was seen between the recordings with or with-
out the vitelline layer (n = 3). Because removal of the vitel-
line layer makes the oocytes fragile we kept it intact
throughout the rest of the experiments.
Oxaliplatin chemistry and oocyte exposure
Oxaliplatin (Fig. 1) was purchased from Sigma-Aldrich
and dissolved in MilliQ water by ultrasonification for 1
hour resulting in a concentration of 6 mM. Oxaliplatin
was then added to the extracellular solution, resulting in a
concentration of typically 60, 120, or 240 μM. In most
cases we measured the effects directly after oxaliplatin
exposure but we also tried application times up to 1 hour.
Some experiments were also performed with over-night
exposure. For these experiments no control recording
could be obtained, making it difficult to explore subtle
effects on the ion channel kinetics. To produce the mono-
chloro monooxalato complex ([Pt(dach)oxCl]-, Fig. 1)
NaCl was added to the oxaliplatin solution to final con-
centrations of 0.2–0.3 M and 1–3 mM, respectively and
heated for about 20 minutes at 37°C and then quenched
on ice. This gives a mixture of oxaliplatin, Pt(dach)Cl2
(Fig. 1, trace amounts), and [Pt(dach)oxCl]- (about 10%)
[23] This mixture was added to the extracellular solution
corresponding to a platinum concentration of 60, 120, or
240 μM.
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